Depressive Illness
Conditions
Keywords
depression, citalopram, bupropion, combination therapy
Brief summary
Depressed patients unremitted after monotherapy with citalopram or bupropion will remit following six weeks treatment with the combination of citalopram and bupropion.
Detailed description
Participants in another study who did not remit during 12 weeks treatment with citalopram (to 40 mg/d) or bupropion (to 450 mg/d) will have citalopram (to 40 mg/d) or bupropion (to 450 mg/d) added for six weeks.
Interventions
DRUGbupropion
FDA approved drug for treating depression
DRUGcitalopram
FDA approved treatment for depression
Sponsors
New York State Psychiatric Institute
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
treatment in this study was determined by treatment received in prior study; i.e., those who had received escitalopram then receive escitalopram + bupropion; those initially taking bupropion then receive escitalopram + bupropion
Eligibility
Sex/Gender
ALL
Age
18 Years to 66 Years
Healthy volunteers
No
Inclusion criteria
* non-remission in Protocol #6559R * age 18-66 * signs informed consent * physically healthy
Exclusion criteria
* bipolar disorder * history of psychosis * history of anorexia nervosa or bulimia * history of seizure disorder, significant brain trauma or other medical reason to suspect increased seizure risk
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hamilton Rating Scale | weeks 6 | Decrease in score for Hamilton Rating Scale for Depression, 17-item version |
Countries
United States
Outcome results
None listed